Latest News

Friday, October 20, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Corrona Partners with National MS Society on Registry to Assess Safety and Efficacy of Therapies

Corrona, LLC and the National Multiple Sclerosis Society will collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS…

Read the full story

Thursday, October 19, 2017 | Product Launches and Updates, Research and Publications

Phenogenetic Database For Stem Cell Models of Neurological Diseases Launched

Based on the results of a novel meta-analysis of all induced pluripotent stem cells, researchers have created an atlas of how cell characteristic in neurological and neurodegenerative diseases are lin…

Read the full story

Wednesday, October 18, 2017 | Concussion & Brain Injury, Research and Publications

National Grant Awarded to Mount Sinai to Continue the New York Traumatic Brain Injury Model System

The National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR) has awarded the Icahn School of Medicine at Mount Sinai’s Department of Rehabilitation Medicine and…

Read the full story

Thursday, October 12, 2017 | FDA Approval/Clearance, Headache & Pain, Phase 3/4 Trials, Research and Publications, Pfizer

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story

Monday, October 09, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Next-Generation VNS System and Implantable Device Approved

LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiv…

Read the full story

Wednesday, October 04, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Product Launches and Updates

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-daily 20mg/mL formulation…

Read the full story

Monday, October 02, 2017 | Dementia & Cognitive Disorders

US Postal Service Issues Alzheimer’s Disease Semipostal Stamps

New stamps for Alzheimer’s disease awareness are coming soon from the US Postal Service. Under its semipostal discretionary program, the Postal Service will issue five stamps over a 10-year peri…

Read the full story

Friday, September 29, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Investigational Low-Dose Fenfluramine Shows Promise in Phase 3 Trial for Dravet Syndrome

Phase 3 findings suggest that the investigational ZX008 (low-dose fenfluramine hydrochloride, Zogenix) is effective for the treatment of Dravet syndrome. The study enrolled 119 patients across sites i…

Read the full story

Wednesday, September 20, 2017 | FDA Approval/Clearance, Headache & Pain, Product Launches and Updates

FDA Approves Intellis Device for Intractable Pain

The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal c…

Read the full story

Friday, September 15, 2017 | Research and Publications, Stroke & Cerebrovascular

Benefits of PFO Closure Confirmed in Publication of Trial Data

Recently published data in The New England Journal of Medicine from three different studies show that closing a patent foramen ovale (PFO) significantly reduces the rate of recurrent stroke compared w…

Read the full story

Friday, September 15, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Briviact Approved as Monotherapy for Partial-Onset Seizures

The FDA has approved a supplemental new drug application for Briviact (brivaracetam, UCB) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 years and older with epile…

Read the full story

Thursday, September 14, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Aptiom Approved for Partial-Onset Seizures in Patients Four Years of Age and Older

The FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Aptiom (eslicarbazepine acetate, Sunovion) to include treatment of partial-onset seizures in childre…

Read the full story

Thursday, September 14, 2017 | Movement Disorders, Research and Publications, Genentech

17 New Genes Linked to Parkinson’s Disease

A new study has discovered 17 novel genetic variants associated with Parkinson’s disease, several of which are considered targets for intervention. Published in Nature Genetics, the genome-wide …

Read the full story

Thursday, September 14, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Vitamin D Levels Tied to Risk of MS

Examining vitamin D levels in the blood may help predict whether a person is at risk of developing multiple sclerosis (MS), according to a large new study published Neurology (September 13). Usin…

Read the full story

Monday, September 11, 2017 | Dementia & Cognitive Disorders, Research and Publications

Blood Test Shown to Accurately Identify Alzheimer’s Disease

A blood test may help identify and diagnose Alzheimer’s disease. In a study published in Proceedings of the National Academy of Sciences of the United States of America, researchers used attenua…

Read the full story
Load More